Physician profile
Anthony Miniaci
NPI 1407891781
$3,126,423.92
in general payments reported to CMS, 2019-2025
20 companies · $251K in 2025
The $251K reported for 2025 was more than what 98% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350K · 2020: $942K · 2021: $478K · 2022: $341K · 2023: $438K · 2024: $327K · 2025: $251K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $855K · Consulting Fee: $142K · Travel and Lodging: $10K · Food and Beverage: $4,922 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $854,559.77 |
| Consulting Fee | $142,372.60 |
| Travel and Lodging | $10,342.85 |
| Food and Beverage | $4,922.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Education | $160.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Anika Therapeutics, INC. | $2,232,797.80 | 2020-2024 | Ovo Motion, Revomotion, Revomotion |
| Arthrosurface Incorporated | $883,628.21 | 2019-2025 | Revomotion, Ovomotion, Wavekahuna |
| Arthrex, INC. | $6,162.87 | 2019-2023 | Arthrex |
| Stryker Corporation | $1,025.75 | 2023-2025 | Mako, Aequalis Perform+ |
| Amniox Medical, INC. | $786.27 | 2019 | |
| Exactech, INC. | $466.95 | 2023-2025 | |
| Zimmer Biomet Holdings, INC. | $338.50 | 2023-2024 | Rosa |
| Shoulder Innovations, INC. | $332.39 | 2024 | Inset System |
| Smith+Nephew, INC. | $202.70 | 2023-2024 | Lens 4k, Real Intelligence |
| Trice Medical, INC. | $153.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $133.64 | 2019 | |
| Catalyst Orthoscience | $127.79 | 2024 | R1 Reverse Shoulder System, Catalyst Csr Shoulder System |
| Djo, LLC | $85.84 | 2025 | |
| Depuy Synthes Sales INC. | $58.06 | 2024 | Monovisc |
| Integra Lifesciences Corporation | $45.09 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rock Medical Orthopedics, INC. | $27.54 | 2022 | |
| Biotissue Holdings INC. | $22.04 | 2019 | |
| Bioventus LLC | $15.70 | 2023 | Exogen Ultrasound Bone Healing System |
| Allergan, INC. | $12.87 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$620,807.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Miniaci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.